{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:08:01Z","timestamp":1791295681734,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:p>Hypertensive cardiac remodeling is accompanied by molecular inflammation and fibrosis, 2 mechanisms that finally affect cardiac function. At cardiac level, aldosterone promotes inflammation and fibrosis, although the precise mechanisms are still unclear. Galectin-3 (Gal-3), a \u03b2-galactoside\u2013binding lectin, is associated with inflammation and fibrosis in the cardiovascular system. We herein investigated whether Gal-3 inhibition could block aldosterone-induced cardiac inflammation and fibrosis and its potential role in cardiac damage associated with hypertension. Aldosterone-salt\u2013treated rats presented hypertension, cardiac inflammation, and fibrosis that were prevented by the pharmacological inhibition of Gal-3 with modified citrus pectin. Cardiac inflammation and fibrosis presented in spontaneously hypertensive rats were prevented by modified citrus pectin treatment, whereas Gal-3 blockade did not modify blood pressure levels. In the absence of blood pressure modifications, Gal-3 knockout mice were resistant to aldosterone-induced cardiac inflammation. In human cardiac fibroblasts, aldosterone increased Gal-3 expression via its mineralocorticoid receptor. Gal-3 and aldosterone enhanced proinflammatory and profibrotic markers, as well as metalloproteinase activities in human cardiac fibroblasts, effects that were not observed in Gal-3\u2013silenced cells treated with aldosterone. In experimental hyperaldosteronism, the increase in Gal-3 expression was associated with cardiac inflammation and fibrosis, alterations that were prevented by Gal-3 blockade independently of blood pressure levels. These data suggest that Gal-3 could be a new molecular mechanism linking cardiac inflammation and fibrosis in situations with high-aldosterone levels, such as hypertension.<\/jats:p>","DOI":"10.1161\/hypertensionaha.115.05876","type":"journal-article","created":{"date-parts":[[2015,8,3]],"date-time":"2015-08-03T22:45:25Z","timestamp":1438641925000},"page":"767-775","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":161,"title":["Galectin-3 Blockade Inhibits Cardiac Inflammation and Fibrosis in Experimental Hyperaldosteronism and Hypertension"],"prefix":"10.1161","volume":"66","author":[{"given":"Ernesto","family":"Mart\u00ednez-Mart\u00ednez","sequence":"first","affiliation":[{"name":"From the Cardiovascular Translational Research, Navarrabiomed (Fundaci\u00f3n Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d\u2019Investigations Cliniques- Plurith\u00e9matique 1433, UMR 1116 Universit\u00e9 de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Calvier","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Translational Research, Navarrabiomed (Fundaci\u00f3n Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d\u2019Investigations Cliniques- Plurith\u00e9matique 1433, UMR 1116 Universit\u00e9 de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaya","family":"Fern\u00e1ndez-Celis","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Translational Research, Navarrabiomed (Fundaci\u00f3n Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d\u2019Investigations Cliniques- Plurith\u00e9matique 1433, UMR 1116 Universit\u00e9 de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Rousseau","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Translational Research, Navarrabiomed (Fundaci\u00f3n Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d\u2019Investigations Cliniques- Plurith\u00e9matique 1433, UMR 1116 Universit\u00e9 de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Jurado-L\u00f3pez","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Translational Research, Navarrabiomed (Fundaci\u00f3n Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d\u2019Investigations Cliniques- Plurith\u00e9matique 1433, UMR 1116 Universit\u00e9 de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana V.","family":"Rossoni","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Translational Research, Navarrabiomed (Fundaci\u00f3n Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d\u2019Investigations Cliniques- Plurith\u00e9matique 1433, UMR 1116 Universit\u00e9 de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Jaisser","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Translational Research, Navarrabiomed (Fundaci\u00f3n Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d\u2019Investigations Cliniques- Plurith\u00e9matique 1433, UMR 1116 Universit\u00e9 de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Translational Research, Navarrabiomed (Fundaci\u00f3n Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d\u2019Investigations Cliniques- Plurith\u00e9matique 1433, UMR 1116 Universit\u00e9 de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Translational Research, Navarrabiomed (Fundaci\u00f3n Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d\u2019Investigations Cliniques- Plurith\u00e9matique 1433, UMR 1116 Universit\u00e9 de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Cachofeiro","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Translational Research, Navarrabiomed (Fundaci\u00f3n Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d\u2019Investigations Cliniques- Plurith\u00e9matique 1433, UMR 1116 Universit\u00e9 de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"L\u00f3pez-Andr\u00e9s","sequence":"additional","affiliation":[{"name":"From the Cardiovascular Translational Research, Navarrabiomed (Fundaci\u00f3n Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d\u2019Investigations Cliniques- Plurith\u00e9matique 1433, UMR 1116 Universit\u00e9 de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2013.12.004"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094695"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs375"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-128X(99)00087-2"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000121426.43044.2B"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-108-4-1216"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2010.159"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2227-684X.2015.01.05"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.02883"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009492"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000149"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2008.070938"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.107.159160"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfr151"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.304964"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.carres.2008.08.038"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.112.300569"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2014.08.002"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.190512"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0177(199804)211:4<306::AID-AJA2>3.0.CO;2-L"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2012-1780"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.008748"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-8807(03)00135-2"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.33.1.212"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mnh.0000203189.57513.76"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.115.05876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:55:54Z","timestamp":1715576154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.115.05876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.115.05876"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.115.05876","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"2015-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-07-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-08-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}